R. de Greef

发表

Operating characteristics of stepwise covariate selection in pharmacometric modeling

Casey B. Davis, F. Gheyas, P. Diderichsen, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma

Manash S. Chatterjee, M. Chatterjee, K. Mayawala, 2016, CPT: pharmacometrics & systems pharmacology.

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

M. Chatterjee, D. Cutler, J. Elassaiss-Schaap, 2016, CPT: pharmacometrics & systems pharmacology.

Effect of a High-Fat Meal on the Pharmacokinetics of 300-Milligram Posaconazole in a Solid Oral Tablet Formulation

Jialin Xu, H. Waskin, P. Dogterom, 2015, Antimicrobial Agents and Chemotherapy.

Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach

S. Cheung, J. Sachs, J. Stone, 2022, eBioMedicine.

Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

E. Cox, K. Vishwanathan, H. Witjes, 2017, British journal of clinical pharmacology.

Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1

K. Yee, L. Wenning, R. de Greef, 2019, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats

M. Danhof, J. Proost, G. Groothuis, 2012, Pharmaceutical Research.

Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects

P. Peeters, R. de Greef, M. Gerrits, 2010, Biopharmaceutics & drug disposition.

Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation.

A. Zandvliet, R. de Greef, M. Prohn, 2016, British journal of clinical pharmacology.

Evaluation of dosing strategy for pembrolizumab for oncology indications

D. D. de Alwis, J. Stone, T. Freshwater, 2017, Journal of Immunotherapy for Cancer.

A PK-PD model-based assessment of sugammadex effects on coagulation parameters.

S. Visser, M. V. van Lierop, P. De Kam, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Jiang Liu, P. Keegan, M. Chatterjee, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial

S. Kang, J. Elassaiss-Schaap, S. P. Kang, 2016, CPT: pharmacometrics & systems pharmacology.

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab

J. Elassaiss-Schaap, V. Sriram, R. Greef, 2016, CPT: pharmacometrics & systems pharmacology.

Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation.

T. Post, T. Kerbusch, R. de Greef, 2016, Contraception.

Asenapine pharmacokinetics and tolerability in a pediatric population

R. Findling, M. Troyer, V. Reddy, 2018, Drug design, development and therapy.

Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale

D. Rujescu, M. Danhof, J. Proost, 2013, Journal of clinical psychopharmacology.

Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia: A Population Pharmacokinetic Exposure‐Response Modeling and Simulation Study

P. Lumbiganon, L. Duley, B. Carvalho, 2019, Journal of clinical pharmacology.

Population Pharmacokinetic Modeling to Evaluate Standard Magnesium Sulfate Treatments and Alternative Dosing Regimens for Women With Preeclampsia

P. Lumbiganon, L. Duley, B. Carvalho, 2018, Journal of clinical pharmacology.

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors

J. Stone, J. Elassaiss-Schaap, T. Freshwater, 2016, CPT: pharmacometrics & systems pharmacology.

Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

T. Campbell, S. Zhou, K. Hege, 2023, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats

M. Danhof, J. Proost, G. Groothuis, 2012, Pharmaceutical Research.

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D2 Receptor Occupancy of Olanzapine in Rats

An Vermeulen, Meindert Danhof, Geny M. M. Groothuis, 2011, Pharmaceutical Research.

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia

H. Waskin, R. Wrishko, E. Mangin, 2019, Open Forum Infectious Diseases.

A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole

H. Waskin, R. de Greef, M. van Iersel, 2018, Antimicrobial Agents and Chemotherapy.

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

Philippe B. Pierrillas, A. Zandvliet, E. Migoya, 2022, Clinical pharmacology and therapeutics.

Model‐based meta‐analysis of non‐small cell lung cancer with standard of care PD‐1 inhibitors and chemotherapy for early development decision making

S. Visser, Helen Zhou, Tai-Tsang Chen, 2023, CPT: pharmacometrics & systems pharmacology.